Injection Anxiety Remains a Long-term Barrier to Medication Adherence in Multiple Sclerosis

Rehabilitation Psychology

Volumn 54, Issue 1, 2009, Pages 116-121

  Turner, Aaron P ^a,b,c,d   Williams, Rhonda M ^a,d   Sloan, Alicia P ^a,b   Haselkorn, Jodie K ^a,b,d  

^a Puget Sound Health Care System   (United States)

^b VA Multiple Sclerosis Center of Excellence West   (United States)

^c VA Center of Excellence in Substance Abuse Treatment and Education   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

anxiety; health behavior; medication adherence; multiple sclerosis

Indexed keywords

ADJUVANTS, IMMUNOLOGIC; ADULT; ANXIETY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; PEPTIDES; SELF ADMINISTRATION; TREATMENT OUTCOME; VETERANS;

EID: 60849112559     PISSN: 00905550     EISSN: None     Source Type: Journal    
DOI: 10.1037/a0014460     Document Type: Article

References (39)

1. Aronson K. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 48 (1997) 74-80
2. Beatty W.W., Paul R.H., Wilbanks S.L., Hames K.A., Blanco C.R., and Goodkin D.E. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology 45 (1995) 718-723
3. Burks J. A practical approach to immunomodulatory therapy for multiple sclerosis. Physical Medicine and Rehabilitation Clinics of North America 16 (2005) 449-466
4. Cohen C., Hellinger J., Johnson M., Staszewski S., Wintfeld N., Patel K., et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clinical Trials 4 (2003) 347-357
5. Colwell Jr. C.W., Pulido P., Hardwick M.E., and Morris B.A. Patient compliance with outpatient prophylaxis: An observational study. Orthopedics 28 (2005) 143-147
6. Daugherty K.K., Butler J.S., Mattingly M., and Ryan M. Factors leading patients to discontinue multiple sclerosis therapies. Journal of the American Pharmacists Association 45 (2005) 371-375
7. Fraser C., Hadjimichael O., and Vollmer T. Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. Journal of Neuroscience Nursing 35 (2003) 163-174
8. Goodin D.S., Frohman E.M., Garmany Jr. G.P., Halper J., Likosky W.H., Lublin F.D., et al. Disease modifying therapies in multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58 (2002) 169-178
9. Goodkin D.E. The natural history of multiple sclerosis (1992), Springer-Verlag, New York
10. Gottberg K., Einarsson U., Ytterberg C., de Pedro Cuesta J., Fredrikson S., von Koch L., et al. Health-related quality of life in a population-based sample of people with multiple sclerosis in Stockholm County. Multiple Sclerosis 12 (2006) 605-612
11. Green J., Kleinman L., Ciesla G., Huang J., Wintfeld N., and Revicki D. Subcutaneous injection survey: Psychometric evaluation of a treatment satisfaction instrument associated with a novel HIV medication. HIV Clinical Trials 3 (2002) 387-395
12. Hadjimichael O., and Vollmer T. Adherence to injection therapy in multiple sclerosis: Patients survey. Neurology 53 (1999) 1190-1197
13. Haynes R., McDonald H., and Garg A. Helping patients follow prescribed treatment. Journal of the American Medical Association 288 (2002) 2880-2883
14. Haynes R., McKibbon K., and Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet 348 (1997) 383-386
15. Johnson K.P. Control of multiple sclerosis relapses with immunomodulating agents. Journal of the Neurological Sciences 256 Suppl. 1 (2007) S23-S28
16. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 33 (1983) 1444-1452
17. Linet O.I., and Ogrinc F.G. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. New England Journal of Medicine 334 (1996) 873-877
18. Lublin F.D., and Reingold S.C. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46 (1996) 907-911
19. Mohr D.C., Boudewyn A.C., Likosky W., Levine E., and Goodkin D.E. Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine 23 (2001) 125-132
20. Mohr D.C., Cox D., Epstein L., and Boudewyn A. Teaching patients to self-inject: Pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. Journal of Behavior Therapy and Experimental Psychiatry 33 (2002) 39-47
21. Mohr D.C., Cox D., and Merluzzi N. Self-injection anxiety training: A treatment for patients unable to self-inject injectable medications. Multiple Sclerosis 11 (2005) 182-185
22. Mohr D.C., Goodkin D.E., Masuoka L., Dick L.P., Russo D., Eckhardt J., et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Multiple Sclerosis 5 (1999) 192-197
23. Mohr D.C., Likosky W., Boudewyn A.C., Marietta P., Dwyer P., Van der Wende J., et al. Side effect profile and adherence to in the treatment of multiple sclerosis with interferon beta-1a. Multiple Sclerosis 4 (1998) 487-489
24. Mulhall J.P. Intracavernosal injection therapy: A practical guide. Techniques in Urology 3 (1997) 129-134
25. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. New England Journal of Medicine 343 (2000) 938-952
26. Osterberg L., and Blaschke T. Adherence to medication. New England Journal of Medicine 353 (2005) 487-497
27. Petrak F., Stridde E., Leverkus F., Crispin A.A., Forst T., and Pfutzner A. Development and validation of a new measure to evaluate psychological resistance to insulin treatment. Diabetes Care 30 (2007) 2199-2204
28. Rao S.M., Leo G.J., Bernardin L., and Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology 41 (1991) 685-691
29. Rio J., Porcel J., Tellez N., Sanchez-Betancourt A., Tintore M., Arevalo M.J., et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis 11 (2005) 306-309
30. Rogers P., and Bullman W. Prescription medicine compliance: A review of the baseline of knowledge. A report of the National Council on Patient Information and Education. Journal of Pharmacoepidemiology 2 (1995) 3
31. Roter D., Hall J., Merisca R., Nordstrom B., Cretin D., and Svarstad B. Effectiveness of interventions to improve patient compliance: A meta-analysis. Medical Care 36 (1998) 1138-1161
32. Schwartz C., Vollmer T., and Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology 52 (1999) 63-70
33. Siegel S.D., Turner A.P., and Haselkorn J.K. Adherence to disease modifying therapies in multiple sclerosis: Does caregiver social support matter?. Rehabilitation Psychology 53 (2008) 73-79
34. Stone V.E. Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice. Clinical Infectious Diseases 33 (2001) 865-872
35. Tremlett H., and Oger J. Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS. Neurology 61 (2003) 551-554
36. Turner A.P., Kivlahan D.R., Sloan A.P., and Haselkorn J.K. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: Utility of the health beliefs model. Multiple Sclerosis 13 (2007) 1146-1152
37. Vollmer T., Hadjimichael O., Preiningerova J., Ni W., and Buenconsejo J. Disability and treatment patterns of multiple sclerosis patients in United States: A comparison of veterans and nonveterans. Journal of Rehabilitation Research and Development 39 (2002) 163-174
38. Vollmer T., Ni W., Stanton S., and Hadjimichael O. The NARCOMS Patient Registry: A resource for investigators. International Journal of MS Care 1 (1999) 12-15
39. Williams R., Turner A., Hatzakis M., Bowen J., Rodriquez A., and Haselkorn J. Prevalence and correlates of depression among veterans with multiple sclerosis. Neurology 64 (2005) 75-80